Twist Bioscience (TWST) Equity Average (2018 - 2026)

Twist Bioscience has disclosed Equity Average across 9 years of filings, most recently posting $455.6 million for Q1 2026.

• In Q1 2026, Equity Average rose 1.69% year-over-year to $455.6 million; the TTM figure through Mar 2026 stood at $455.6 million (up 1.69% YoY), while the FY2025 annual figure was $472.8 million, down 13.73% from the prior year.
• Equity Average declined to $455.6 million in Q1 2026, from $464.5 million in the prior quarter.
• Over the last five years, Equity Average for TWST reached as high as $842.0 million in Q2 2022 and fell as low as $448.0 million in Q1 2025.
• The 5-year median for Equity Average is $575.1 million (2024), against an average of $597.8 million.
• Annual changes were most pronounced in 2022 — Equity Average surged 37.51% — and 2024, when it dropped 24.76%.
• A 5-year view of Equity Average shows it stood at $767.9 million in 2022, then slipped by 20.98% to $606.7 million in 2023, then dropped by 23.47% to $464.3 million in 2024, then climbed by 0.05% to $464.5 million in 2025, then declined by 1.92% to $455.6 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $455.6 million, $464.5 million, and $475.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.